

inside **blood** commentary

5 JANUARY 2017 | VOLUME 129, NUMBER 1

● ● ● CLINICAL TRIALS AND OBSERVATIONS

Comment on Kim et al, page 38

Antecedent CHIP in CML?

Matthew J. Walter WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

In this issue of *Blood*, Kim et al provide evidence that the t(9;22) translocation (ie, Philadelphia chromosome, or Ph), coding for the *BCR/ABL* gene rearrangement, is not always the first mutation acquired in chronic myeloid leukemia (CML).¹ These results are consistent with prior smaller studies and indicate that CML can sometimes arise from a preexisting Ph-negative (Ph⁻) hematopoietic clone already harboring additional gene mutations. This work also adds to the growing body of evidence suggesting that *BCR/ABL* expression alone may not be sufficient to induce CML.


Thirty-five years ago, Fialkow et al first suggested that the *BCR/ABL* translocation may not always be the initiating mutation in CML. The authors reported that both Ph⁻ and Ph⁺ cells from patients with CML can be clonal, based on the pattern of X-chromosome inactivation.² This provided evidence that in some patients, Ph may arise in a preexisting Ph⁻ clonal population, akin to clonal hematopoiesis of indeterminate potential (CHIP).³ Decades later, Schmidt et al reached similar conclusions by sequencing 25 genes in

blood cells from 29 patients with CML.⁴ Ph⁻ and Ph⁺ cells were isolated from patients with CML, including a subset of patients that appeared to develop clonal cytogenetic abnormalities in their Ph⁻ cells during treatment with a tyrosine kinase inhibitor (TKI). Several patients had the same gene mutation present in both their Ph⁻ and Ph⁺ cells, including 1 patient with a *DNMT3A* mutation in both cell types. These data provided further evidence that Ph can arise in an expanded Ph⁻ clone carrying a CHIP-

related gene mutation (ie, a “preleukemic” clone with CHIP).

Several lines of evidence from mouse and human studies also suggest that *BCR/ABL* expression alone may not be sufficient for disease induction. Although overexpression of *BCR/ABL* using a retrovirus can induce a myeloproliferative disease in mice, a knock-in model expressing physiologic levels of human *BCR/ABL* p210 from the mouse *Bcr* locus did not induce leukemia.⁵ In addition, there are marked strain differences (DBA/2 vs C57BL/6) in disease induction after *BCR/ABL* retroviral overexpression,⁶ suggesting that additional inherited polymorphisms influence the ability of *BCR/ABL* to induce disease. Finally, several groups have identified individuals who express *BCR/ABL* without evidence of CML.⁷ Collectively, the data indicate that additional genetic mutations or variants may cooperate with *BCR/ABL* to induce CML. Identifying mutations that co-occur with Ph in CML was explored in the current study.

To investigate the acquisition, persistence, and clearance of gene mutations in CML, Kim et al sequenced 92 myeloid malignancy-associated genes in hematopoietic cells from 100 patients with CML at diagnosis (all harboring *BCR/ABL*) and at follow-up after treatment with a TKI.¹ The authors used T cells isolated from diagnostic samples as control tissue and identified 37 patients with gene mutations present in at least 1 timepoint. Chromatin modification and DNA methylation genes (epigenetic modifiers) were the most common category of mutant genes in the cohort at diagnosis, and spliceosome gene mutations were infrequent. Using 2013 European LeukemiaNet response criteria, patients were classified as TKI responsive, resistant, or progressed on therapy. The fraction of patients with at least 1 mutation was highest among the group that progressed on therapy, intermediate among resistant patients, and lowest in patients who responded to TKIs. As expected, *ABL1*



Preleukemic cells in CML and clonal hematopoiesis after TKI therapy. A hematopoietic stem and progenitor cell acquires a gene mutation or mutations and clonally expands (ie, becomes a preleukemia clone). A preleukemia cell gains a Ph chromosome and expands, and clinical CML develops. After treatment with a TKI, Ph⁺ cells are eradicated, and residual mutant Ph⁻ preleukemic cells expand and contribute to clonal hematopoiesis.

kinase domain mutations were specific to TKI nonresponsive patients.

Overall, up to 10% of patients had persistence of gene mutations in their follow-up samples after responding to TKI therapy, some without detectable mutations in their diagnostic T cells. This indicates that the t(9;22) translocation was not the first mutation in their cells (see figure). In addition, nearly all the bone marrow cells were clonal in several of these patients at follow-up, even when a 4.0 log reduction in *BCR/ABL* levels was achieved. These results indicate that Ph⁻ clonal hematopoiesis can occur in patients with CML after TKI therapy. The majority of patients with CML with evidence of clonal hematopoiesis after TKI treatment had a mutation in a gene recently identified in healthy individuals with CHIP, including mutations in *DNMT3A*, *TET2*, *ASXL1*, *BCOR*, and *CREBBP*.³ These mutations were present in both diagnosis and follow-up samples. Collectively, the data suggest that residual “preleukemic” mutant cells lacking *BCR/ABL* can expand and contribute to clonal hematopoiesis after successful TKI treatment, a finding similar to that recently described for acute myeloid leukemia.⁸

Although the results are provocative, there are several technical issues to consider. It would be interesting to know whether *BCR/ABL* was detected in the T-cell fraction. Early reports suggested that *BCR/ABL* may occur in T cells,⁹ a finding that could alter the interpretation of whether a patient had preleukemic mutations in Ph⁻ cells vs mutations in Ph⁺ stem cells that were capable of producing T cells. Because T cells were used as matched “normal” samples for variant calling, mutations present at high levels in T cells may be missed in diagnostic or follow-up samples (ie, false-negative mutations). Therefore, the authors used several approaches to identify preleukemic mutations present in T cells, including classifying a variant as somatic in a sample, regardless of the T-cell variant allele fraction (VAF) for that patient, if the same variant was identified as somatic in at least 1 other patient, using their matched T cells. Two variants (*TET2* p.F868L and *ASXL1* p.630_637del) were identified using this approach, and all 5 patients with mutation pattern 4 or 5 harbored one of the variants. These patients had similar or higher VAFs in their T cells compared with diagnostic or follow-up samples. The authors concluded

that these 5 patients likely had preleukemic mutations. However, the *TET2* p.F868L variant occurs at 1.5% in the East Asian population,¹⁰ raising the possibility that this variant calling approach may have limitations that could influence the results of the study.

The authors note that patients with CML with clonal hematopoiesis responded well to TKI therapy and maintained durable responses. Larger studies with longer follow-up will be needed to confirm this finding, and possibly to address whether clonal hematopoiesis is prognostic for patients with CML who discontinue TKI therapy. This study was not designed to determine whether CML arises from antecedent CHIP in some patients, but the data strongly suggest this does occur. This study also provides additional evidence suggesting *BCR/ABL* may not be sufficient on its own to induce CML in all patients. Certain antecedent mutations associated with CHIP may create a state of “fitness” that makes it more likely that *BCR/ABL* will move a cell forward to clinically recognizable CML. Identifying the full complement of genetic events that cooperate with *BCR/ABL*, using more unbiased sequencing approaches (eg, exome or whole genome sequencing), could nominate novel genetic dependencies that cooperate with *BCR/ABL* to induce CML.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

1. Kim T, Tyndel MS, Kim HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. *Blood*. 2017; 129(1):38-47.
2. Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. *Blood*. 1981;58(1):158-163.
3. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood*. 2015;126(1):9-16.
4. Schmidt M, Rinke J, Schäfer V, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. *Leukemia*. 2014;28(12):2292-2299.
5. Foley SB, Hildenbrand ZL, Soyombo AA, et al. Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia. *Cell Reports*. 2013;5(1):51-60.
6. Elefanti AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. *EMBO J*. 1990; 9(4):1069-1078.
7. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. *Blood*. 1995;86(8):3118-3122.
8. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of preleukaemic haematopoietic stem cells in acute leukaemia. *Nature*. 2014;506(7488):328-333.
9. Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN. Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. *J Clin Invest*. 1978;62(4):815-823.
10. Lek M, Karczewski KJ, Minikel EV, et al; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016; 536(7616):285-291.

DOI 10.1182/blood-2016-11-746842

© 2017 by The American Society of Hematology

● ● ● HEMATOPOIESIS AND STEM CELLS

Comment on Cantor and David, page 60

HSCs: they can't live without their SINs

Vincent van den Boom UNIVERSITY MEDICAL CENTER GRONINGEN

In this issue of *Blood*, Cantor and David pinpoint Sin3B as an essential factor that regulates quiescence of long-term hematopoietic stem cells (LT-HSCs) and is required for their differentiation. The authors show that, under conditions of replicative stress, conditional deletion of Sin3B leads to an accumulation of LT-HSCs and a concomitant loss of differentiated blood cell types.¹

The capacity of LT-HSCs to undergo self-renewal upon cell division is a key trait that ensures a continuous output of various differentiated hematopoietic cell types in the blood system over the life span of each

individual.² Sudden changes in blood cell homeostasis (ie, as a consequence of inflammation, blood loss, or treatment with chemotherapeutics) require an immediate response from the LT-HSC compartment by



blood[®]

2017 129: 3-4

doi:10.1182/blood-2016-11-746842

Antecedent CHIP in CML?

Matthew J. Walter

Updated information and services can be found at:

<http://www.bloodjournal.org/content/129/1/3.full.html>

Articles on similar topics can be found in the following Blood collections

[Free Research Articles](#) (4382 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>